Polianta Ltd’s Acadia Pharmaceuticals ACAD Stock Holding History

Polianta Ltd’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-23,200	Closed	-$992K	–	63
2019 Q4	$992K	Buy	+23,200	New	+$1.01M	0.6%	60

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Polianta Ltd's ACAD Position: Q1 2020 in Review

Polianta Ltd sold out of Acadia Pharmaceuticals (ACAD) in Q1 2020, closing a stake of 23,200 shares — an estimated $992K sold.

Polianta Ltd first reported a position in ACAD in Q4 2019 and held it in 1 quarter. The position peaked at $992K in Q4 2019. 245 funds tracked by Wall St. Rank hold ACAD as of Q1 2020.

Polianta Ltd reported no remaining Acadia Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
Polianta Ltd sold 23,200 Acadia Pharmaceuticals shares in Q1 2020, an estimated $992K.
Polianta Ltd first reported a position in Acadia Pharmaceuticals in Q4 2019 and held it in 1 quarter.
Polianta Ltd's Acadia Pharmaceuticals position peaked at $992K in Q4 2019.
245 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2020.

Based on Polianta Ltd's 13F filing for Q1 2020, filed 7 Apr 2020.